Targeting PD-L1 Initiates Effective Antitumor Immunity in a Murine Model of Cushing Disease.
Hanna R KemenyAladine A ElsamadicyS Harrison FarberCosette D ChampionSelena J LorreyPakawat ChongsathidkietKarolina I WoronieckaXiuyu CuiSteven H ShenKristen E RhodinVadim TsvankinJeffrey EverittLuis Sanchez-PerezPatrick HealyRoger E McLendonPatrick J CoddIan F DunnPeter E FecciPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2019)
This suggests that immunotherapy, particularly blockade of the PD1/PD-L1 axis, may be a novel therapeutic option for refractory Cushing disease. Clinical investigation is encouraged.
Keyphrases